Article ; Online: A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
2020 Volume 149, Issue 3, Page(s) 437–445
Abstract: Purpose: This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered daily during 6 weeks of radiation therapy to children with newly diagnosed ... ...
Abstract | Purpose: This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered daily during 6 weeks of radiation therapy to children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) PATIENTS & METHODS: Children and young adults < 22 years of age with newly diagnosed disease and no prior chemotherapy or radiation therapy were eligible. Children with HGG were required to have an inoperable or incompletely resected tumor. Eligible patients received standard radiation therapy to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide daily during radiation therapy in a standard 3 + 3 Phase I dose escalation design. Following completion of radiation therapy, patients had a 2-week break followed by maintenance lenalidomide at 116 mg/m Results: Twenty-nine patients (age range 4-19 years) were enrolled; 24 were evaluable for dose finding (DIPG, n = 13; HGG, n = 11). The MTD was not reached at doses of lenalidomide up to 116 mg/m Conclusion: The RP2D of lenalidomide administered daily during radiation therapy is 116 mg/m |
---|---|
MeSH term(s) | Adolescent ; Adult ; Angiogenesis Inhibitors/pharmacokinetics ; Angiogenesis Inhibitors/therapeutic use ; Brain Stem Neoplasms/pathology ; Brain Stem Neoplasms/therapy ; Chemoradiotherapy/methods ; Child ; Child, Preschool ; Diffuse Intrinsic Pontine Glioma/pathology ; Diffuse Intrinsic Pontine Glioma/therapy ; Female ; Follow-Up Studies ; Humans ; Lenalidomide/pharmacokinetics ; Lenalidomide/therapeutic use ; Male ; Maximum Tolerated Dose ; Prognosis ; Tissue Distribution ; Young Adult |
Chemical Substances | Angiogenesis Inhibitors ; Lenalidomide (F0P408N6V4) |
Language | English |
Publishing date | 2020-10-11 |
Publishing country | United States |
Document type | Clinical Trial, Phase I ; Journal Article |
ZDB-ID | 604875-4 |
ISSN | 1573-7373 ; 0167-594X |
ISSN (online) | 1573-7373 |
ISSN | 0167-594X |
DOI | 10.1007/s11060-020-03627-0 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1825: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.